Boehringer Ingelheim will invest 11 billion euros in Research and Development in the next five years to accelerate the discovery of next generation medical...
• 11 billion euro R&D programme through 2020, with 5 billion euro dedicated to pre-clinical R&D and 1.5 billion euro planned for cooperation with...
Time is of the essence for millions living with ‘neglected’ lung disease
Your Time campaign calls for earlier action in COPDWHO expects COPD to be the third leading cause of death worldwide by 2030 - exceeded...
Boehringer Ingelheim partners with leading scientific institutions in inflammatory bowel disease research
Collaborations aim to speed research and development approaches in Crohn’s disease and ulcerative colitisIcahn School of Medicine, Massachusetts General Hospital, The Scripps Research Institute...
Boehringer Ingelheim Announces Completed Enrollment of Phase III Clinical Trial for Biosimilar Candidate to Adalimumab
Phase III clinical trial for BI695501, a biosimilar candidate for AbbVie’s Humira®, fully enrolledRecently announced Phase I trial results show pharmacokinetic bioequivalence of BI695501...
CHEST: New Sub-Analyses Show Improvement in COPD Patient Outcomes with Spiolto® Respimat®
Studies show significant improvement with Spiolto® Respimat® in lung function across a range of age groups of patients* with COPD studied compared to tiotropium,...
AstraZeneca announces updated progression free survival data for investigational non-small cell lung cancer medicine AZD9291
Late breaking data presented at European Lung Cancer Congress 2015 shows delay in disease progression of over a year AstraZeneca today announced latest data...
AstraZeneca enters strategic immuno-oncology collaboration with Celgene Corporation to develop PD-L1 inhibitor programme for patients with serious blood cancers
AstraZeneca and MedImmune, the Company’s global biologics research and development arm, today announced that they have entered into an exclusive collaboration agreement with Celgene...
Subscribe Our Newsletter
White Papers
The Future of Digital Health
The pharmaceutical industry is acutely aware that the future of health and care, particularly in the United States, are trending toward a digital revolution....
Five Best Practices to Deliver Exceptional Multichannel Experiences
A one-size-fits-all customer journey no longer works. In the age of the consumer, the quality of the interaction is paramount. In this paper, we...
The Impact and Use of Social Media in Pharmacovigilance
Social media presents new channels and methods for biopharmaceutical companies to move away from traditional pharmacovigilance (PV) systems and safety reporting methods towards more...